Healthcare technology firm Koneksa has expanded collaboration with life sciences consulting firm SSI Strategy to scale evidence-based digital biomarker adoption in clinical trials.
The digital biomarker solutions of Koneksa include a platform which allows research sponsors and clinical sites to seamlessly aggregate data, in real-time, from patient diaries, devices, ePROs, and clinical assessments, to provide a complete view of a person’s health.
SSI will expand the medical strategy division of Koneksa, mainly in translational and clinical drug development, as part of the collaboration.
This partnership will also provide both companies’ existing clients with a streamlined relationship offering technical, scientific, and delivery expertise across all clinical trial and product lifecycle phases.
Through the collaboration, Koneksa clients will gain access to a PhDs and MDs team at SSI, with expertise in drug development, while SSI clients will gain access to the expertise of Koneksa in digital biomarker development and usage.
Koneksa president and chief operating officer Vik Shah said: “This synergistic partnership is a combination of resources, talent, and expertise across two leading science-based organisations, with a mission of optimising and accelerating therapies for patients in need, through greater adoption of digital biomarkers in clinical studies.
“This expanded partnership is in response to the growing interest from life sciences companies to have an in-house digital biomarker solution, and SSI will enable us to rapidly scale our medical and scientific functions to meet this demand.
“SSI will also be able to provide clients with leading expertise in digital biomarkers from the Koneksa team to accelerate clinical trials and bring new life-saving therapies to patients faster.”
